Skip to content
OpenCapital
Get started

Puma Biotechnology PBYI Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$44.8MBeat by $2.8M
EPS-$0.04Beat by $0.09
Revenue estimate$42.0M
EPS estimate-$0.13

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$53.0M
EPS estimate$0.04

Versus estimates

Revenue

Q1 2026$44.8MBeat by $2.8M
Q4 2025$59.9MMiss by $8.7MQ3 2025$54.5MMiss by $14.1MQ2 2025$52.4MBeat by $1.4MQ1 2025$46.0MMiss by $6.7MQ4 2024$59.1MBeat by $6.6M

Diluted EPS

Q1 2026-$0.04Beat by $0.09
Q4 2025$0.29Beat by $0.05Q3 2025$0.21Beat by $0.12Q2 2025$0.15Beat by $0.04Q1 2025$0.10Beat by $0.08Q4 2024$0.43Beat by $0.33

Ask the moment Puma Biotechnology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Puma Biotechnology report Q1 2026 earnings?
Puma Biotechnology (PBYI) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Puma Biotechnology's Q1 2026 revenue and EPS?
Puma Biotechnology reported revenue of $44.8M and eps of $-0.04 for Q1 2026.
Did Puma Biotechnology beat estimates in Q1 2026?
Revenue beat the consensus estimate of $42.0M by $2.8M. EPS beat the consensus estimate of $-0.13 by $0.09.
How did Puma Biotechnology's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.6% from $46.0M a year earlier.
Where can I find Puma Biotechnology's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-015621) and the 10-Q periodic report (0001437749-26-015633) directly on SEC EDGAR. The filing index links above go to sec.gov.